Merck fined AUD$75,000 for Movectro advertising

Mavenclad is an oral treatment for relapsing MS and active secondary progressive MS.
Post Reply
User avatar
hwebb
Family Elder
Posts: 361
Joined: Thu Nov 26, 2009 3:00 pm
Location: Melbourne, Australia
Contact:

Merck fined AUD$75,000 for Movectro advertising

Post by hwebb » Tue Apr 19, 2011 2:55 am

Merck Serono, makers of leukemia drug Cladribine (now marketed as MS drug Movectro) have been fined A$75,000 for breach of the Medicines Australia Code of Conduct for their Movectro advertisement on the Australian Channel 7 news last year. The advertisement was presented as a news item, and was performed by neurologist Dr Bill Carroll (Multiple Sclerosis Research Australia) and MS Australia.

In Australia, it is not legal to advertise a prescription medication direct to the consumer.

I’m sure Merck Serono still view this as cheap advertising.

Post Reply